Dr. Horn on the Role of Mobocertinib in NSCLC

Dr. Horn on Incorporating T790M-Mutant NSCLC Agents Into NCCN GuidelinesПодробнее

Real-World Comparison Assesses Mobocertinib in NSCLC With EGFR Exon 20Подробнее

Dr. Horn on the FDA Approval of Atezolizumab Plus Bevacizumab and Chemotherapy in NSCLCПодробнее

Dr. Horn on Selecting Inhibitors for ALK+ NSCLCПодробнее

Dr. Leora Horn on Toxicities With Immunotherapy in Lung CancerПодробнее

Mobocertinib for previously treated NSCLC with EFGR mutationsПодробнее

Dr. Horn on Monitoring Response and Resistance to Ensartinib in ALK+ NSCLCПодробнее

NSCLC With EGFR Exon 20 Shows Benefit With Mobocertinib Over ChemotherapyПодробнее

Amivantamab and Mobocertinib for EGFR Exon-20 Disease - Lung Cancer Video LibraryПодробнее

Efficacy of mobocertinib in patients previously treated with TKIsПодробнее

Lung Cancer Video Library 2020 - PATEL Emerging Molecular Targets in NSCLC EGFR Exon 20Подробнее

ASCO 2021 Lung Recap: Amivantamab and Mobocertinib for EGFR Exon 20Подробнее

Latest in EGFR-positive NSCLC with exon 20 insertion mutationsПодробнее

Amivantamab and Mobocertinib: Side Effects and Treatment Timing - Lung CancerПодробнее

ASCO 2019: Dr. Horn Highlights Progress in Lung CancerПодробнее

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicityПодробнее

Dr. Horn on Updated Data From IMpower133 in Small Cell Lung CancerПодробнее

WU-KONG1: sunvozertinib in NSCLC with EGFR exon 20 insertion mutationsПодробнее

Dr. Horn Discusses Next Steps With Atezolizumab in SCLCПодробнее